Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 26 Sep 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
- 26 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 06 Jan 2016 Planned End Date changed from 1 Dec 2014 to 1 Mar 2016 as reported by clinicalTrials.gov record.